XNASINDV
Market cap1.70bUSD
Dec 26, Last price
12.32USD
1D
2.75%
1Q
22.71%
IPO
-45.89%
Name
Indivior PLC
Chart & Performance
P/E
849.33
P/S
1.55
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
-1.15%
Rev. gr., 5y
2.63%
Revenues
1.09b
+23.55%
Net income
2m
P
CFO
-315m
L+7,920.73%
Earnings
Feb 20, 2025
Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,093,000 23.55% | 884,630 13.78% | 777,482 12.73% | |||||
Cost of revenue | 1,103,000 | 1,002,567 | 619,719 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (10,000) | (117,937) | 157,763 | |||||
NOPBT Margin | 20.29% | |||||||
Operating Taxes | (1,000) | (41,237) | (14,744) | |||||
Tax Rate | ||||||||
NOPAT | (9,000) | (76,700) | 172,507 | |||||
Net income | 2,000 -103.84% | (52,037) -125.38% | 205,000 -229.94% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (29,000) | (86,401) | (98,291) | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 12,000 | 11,059 | 10,978 | |||||
Long-term debt | 313,000 | 267,437 | 274,462 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 378,084 | 464,496 | 584,853 | |||||
Net debt | (125,809) | (717,858) | (814,243) | |||||
| Cash flow | ||||||||
Cash from operating activities | (315,000) | (3,927) | 346,967 | |||||
CAPEX | (8,000) | (5,891) | (33,419) | |||||
Cash from investing activities | (100,361) | (218,948) | (13,761) | |||||
Cash from financing activities | (46,000) | (98,183) | (92,394) | |||||
FCF | (30,193) | (67,345) | 180,693 | |||||
| Balance | ||||||||
Cash | 410,000 | 897,825 | 1,099,844 | |||||
Long term investments | 40,809 | 98,530 | (160) | |||||
Excess cash | 396,159 | 952,123 | 1,060,809 | |||||
Stockholders' equity | (9,132) | 43,232 | 195,617 | |||||
Invested Capital | 671,975 | 712,831 | 834,364 | |||||
ROIC | 20.45% | |||||||
ROCE | 15.32% | |||||||
| EV | ||||||||
Common stock shares outstanding | 141,800 | 139,012 | 154,228 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 18,675 | (97,319) | 179,387 | |||||
EV/EBITDA | ||||||||
Interest | 37,000 | 29,000 | 26,000 | |||||
Interest/NOPBT | 16.48% | |||||||